stockportfolio.pro
Rigel Pharmaceuticals, Inc. (RIGL)
Healthcare · Biotechnology · NasdaqGS
Rigel Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.38M | $4.48M | $44.51M | $59.29M | $108.62M | $149.24M | $120.24M | $116.88M | $179.28M | $294.28M |
| Gross profit | — | — | $44.22M | $58.38M | $107.73M | $148.15M | $118.49M | $109.77M | $160.63M | $274.66M |
| Net income | $-69.22M | $-77.99M | $-70.48M | $-66.89M | $-29.74M | $-17.91M | $-58.57M | $-25.09M | $17.48M | $367.02M |
| Net margin | -339.6% | -1739.3% | -158.3% | -112.8% | -27.4% | -12.0% | -48.7% | -21.5% | 9.8% | 124.7% |
Source: Rigel Pharmaceuticals, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
What growth is priced into RIGL stock?
At today's market cap of $588.37M, Rigel Pharmaceuticals, Inc. is priced for free-cash-flow growth of about 7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $31.07M from the FY ending 2024-12-31). For comparison, revenue 22.1%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 17 years of Rigel Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track RIGL in your portfolio →
Rigel Pharmaceuticals, Inc. financial history by metric
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Rigel Pharmaceuticals, Inc. — frequently asked questions
What is Rigel Pharmaceuticals, Inc.'s revenue?
Rigel Pharmaceuticals, Inc. (RIGL) reported revenue of $294.28M for fiscal year 2025, up 64.1% from the prior year, according to its SEC filings.
Is Rigel Pharmaceuticals, Inc. profitable?
Yes. RIGL earned net income of $367.02M in fiscal 2025, a net margin of 124.7%.
What is RIGL's P/E ratio?
Rigel Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 1.6 based on the latest data in our nightly-refreshed cache.
How fast is Rigel Pharmaceuticals, Inc. growing?
RIGL's revenue grew at roughly 22.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Rigel Pharmaceuticals, Inc. have?
As of fiscal year 2025, RIGL carried roughly $52.29M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Rigel Pharmaceuticals, Inc.'s gross margin?
RIGL's gross margin was 93.3% in fiscal 2025 — gross profit of $274.66M on revenue of $294.28M.
What is Rigel Pharmaceuticals, Inc.'s market cap?
Rigel Pharmaceuticals, Inc. (RIGL) has a market capitalization of about $588.37M, based on the latest data in our nightly-refreshed cache.
When does Rigel Pharmaceuticals, Inc.'s fiscal year end?
RIGL's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into RIGL stock?
At today's market cap of $588.37M, Rigel Pharmaceuticals, Inc. is priced for free-cash-flow growth of about 7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $31.07M from the FY ending 2024-12-31). For comparison, revenue 22.1%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Rigel Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.